Compare
Guardant Health, Inc. vs Veracyte, Inc. vs Castle Biosciences Inc vs Fulgent Genetics, Inc.
| Latest fiscal year | Guardant Health, Inc. GH | Veracyte, Inc. VCYT | Castle Biosciences Inc CSTL | Fulgent Genetics, Inc. FLGT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $982.02M | $517.14M | $344.23M | $322.67M |
| Revenue growth (YoY) | +32.9% | +16.0% | +3.7% | +13.8% |
| Gross margin | 64.5% (computed) | 70.1% | 79.4% (computed) | 40.6% |
| Operating margin | -44.5% | 11.2% | -12.4% | -28.2% |
| Net margin | -42.4% | 12.8% | -7.0% | -18.8% |
| Net income | -$416.28M | $66.35M | -$24.16M | -$60.51M |
| EPS (Diluted) | -$3.32 | $0.82 | -$0.83 | n/a |
| Operating cash flow | -$184.76M | $136.31M | $64.35M | -$101.64M |
| Free cash flow | -$233.07M | $126.63M | $28.33M | -$124.21M |
| Cash & equivalents | $378.20M | $362.58M | $116.73M | $50.19M |
| Total assets | $2.01B | $1.41B | $578.56M | $1.21B |
| Total liabilities | $2.11B | $96.44M | $107.68M | $106.81M |
| Shareholders' equity | -$99.31M | $1.31B | $470.87M | $1.11B |
| Return on year-end equity | n/a | 5.1% | -5.1% | -5.4% |
| Shares outstanding | 130.64M | 79.36M | 29.69M | 31.08M |
Revenue, most recent five fiscal years
| Fiscal year | Guardant Health, Inc. | Veracyte, Inc. | Castle Biosciences Inc | Fulgent Genetics, Inc. |
|---|---|---|---|---|
| Latest | $982.02M Ended 2025-12-31 | $517.14M Ended 2025-12-31 | $344.23M Ended 2025-12-31 | $322.67M Ended 2025-12-31 |
| 1 year earlier | $739.02M Ended 2024-12-31 | $445.76M Ended 2024-12-31 | $332.07M Ended 2024-12-31 | $283.47M Ended 2024-12-31 |
| 2 years earlier | $563.95M Ended 2023-12-31 | $361.05M Ended 2023-12-31 | $219.79M Ended 2023-12-31 | $289.21M Ended 2023-12-31 |
| 3 years earlier | $449.54M Ended 2022-12-31 | $296.54M Ended 2022-12-31 | $137.04M Ended 2022-12-31 | $618.97M Ended 2022-12-31 |
| 4 years earlier | $373.65M Ended 2021-12-31 | $219.51M Ended 2021-12-31 | $94.08M Ended 2021-12-31 | $992.58M Ended 2021-12-31 |